518 related articles for article (PubMed ID: 10946997)
1. Potent cyclic monomeric and dimeric peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion based on the Ile-Leu-Asp-Val tetrapeptide.
Dutta AS; Crowther M; Gormley JJ; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Jamieson A; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
J Pept Sci; 2000 Jul; 6(7):321-41. PubMed ID: 10946997
[TBL] [Abstract][Full Text] [Related]
2. Potent cyclic peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion. Discovery of compounds like cyclo(MePhe-Leu-Asp-Val-D-Arg-D-Arg) (ZD7349) compatible with depot formulation.
Dutta AS; Gormley JJ; Coath M; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Ferguson R; Halterman T; Jamieson A; Moors JA; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
J Pept Sci; 2000 Aug; 6(8):398-412. PubMed ID: 10969869
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory activity of c(ILDV-NH(CH2)5CO), a novel, selective, cyclic peptide inhibitor of VLA-4-mediated cell adhesion.
Haworth D; Rees A; Alcock PJ; Wood LJ; Dutta AS; Gormley JJ; Jones HB; Jamieson A; Reilly CF
Br J Pharmacol; 1999 Apr; 126(8):1751-60. PubMed ID: 10372817
[TBL] [Abstract][Full Text] [Related]
4. Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses.
Lin Kc; Ateeq HS; Hsiung SH; Chong LT; Zimmerman CN; Castro A; Lee WC; Hammond CE; Kalkunte S; Chen LL; Pepinsky RB; Leone DR; Sprague AG; Abraham WM; Gill A; Lobb RR; Adams SP
J Med Chem; 1999 Mar; 42(5):920-34. PubMed ID: 10072689
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and opioid activity of side-chain-to-side-chain cyclic dynorphin A-(1-11) amide analogues cyclized between positions 2 and 5. 1. Substitutions in position 3.
Vig BS; Murray TF; Aldrich JV
J Med Chem; 2004 Jan; 47(2):446-55. PubMed ID: 14711314
[TBL] [Abstract][Full Text] [Related]
6. Potent alpha 4 beta 1 peptide antagonists as potential anti-inflammatory agents.
Jackson DY; Quan C; Artis DR; Rawson T; Blackburn B; Struble M; Fitzgerald G; Chan K; Mullins S; Burnier JP; Fairbrother WJ; Clark K; Berisini M; Chui H; Renz M; Jones S; Fong S
J Med Chem; 1997 Oct; 40(21):3359-68. PubMed ID: 9341911
[TBL] [Abstract][Full Text] [Related]
7. Endothelin (ET)-1-induced inhibition of ATP release from PC-12 cells is mediated by the ETB receptor: differential response to ET-1 on ATP, neuropeptide Y, and dopamine levels.
Gardner A; Westfall TC; Macarthur H
J Pharmacol Exp Ther; 2005 Jun; 313(3):1109-17. PubMed ID: 15687374
[TBL] [Abstract][Full Text] [Related]
8. The novel recognition site in the C-terminal heparin-binding domain of fibronectin by integrin alpha 4 beta 1 receptor on HL-60 cells.
Mohri H; Katoh K; Iwamatsu A; Okubo T
Exp Cell Res; 1996 Feb; 222(2):326-32. PubMed ID: 8598221
[TBL] [Abstract][Full Text] [Related]
9. Lasioglossins: three novel antimicrobial peptides from the venom of the eusocial bee Lasioglossum laticeps (Hymenoptera: Halictidae).
Cerovský V; Budesínský M; Hovorka O; Cvacka J; Voburka Z; Slaninová J; Borovicková L; Fucík V; Bednárová L; Votruba I; Straka J
Chembiochem; 2009 Aug; 10(12):2089-99. PubMed ID: 19591185
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of potent and selective alpha(4)beta(7) integrin antagonists.
Boer J; Gottschling D; Schuster A; Semmrich M; Holzmann B; Kessler H
J Med Chem; 2001 Aug; 44(16):2586-92. PubMed ID: 11472212
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of potent, highly selective vasopressin hypotensive agonists.
Stoev S; Cheng LL; Manning M; Wo NC; Szeto HH
J Pept Sci; 2006 Sep; 12(9):592-604. PubMed ID: 16625682
[TBL] [Abstract][Full Text] [Related]
12. Effects of amino acids and chirality for molecular folding of desoxazoline-ascidiacyclamide derivatives: X-ray crystal structures of four cyclic octapeptides including unusual amino acids, cyclo(-Ile-aThr-D-Val-Thz-)(2), cyclo(-Ala-aThr-D-Val-Thz-Ile-aThr-D-Val-Thz-), cyclo(-Val-aThr-D-Val-Thz-Ile-aThr-D-Val-Thz-), and cyclo(-Ile-aThr-Val-Thz-Ile-aThr-D-Val-Thz-).
Asano A; Doi M; Kobayashi K; Arimoto M; Ishida T; Katsuya Y; Mezaki Y; Hasegawa H; Nakai M; Sasaki M; Taniguchi T; Terashima A
Biopolymers; 2001 Mar; 58(3):295-304. PubMed ID: 11169389
[TBL] [Abstract][Full Text] [Related]
13. Cyclic peptides. XIV. Syntheses of [4-l-leucine]-, [4-D-leucine]-, and [3-L-proline, 4-D-leucine]-Cyl-2.
Yasutake A; Aoyagi H; Sada I; Kato T; Izumiya N
Int J Pept Protein Res; 1982 Sep; 20(3):246-53. PubMed ID: 7129757
[TBL] [Abstract][Full Text] [Related]
14. A cyclic hexapeptide is a potent antagonist of alpha 4 integrins.
Vanderslice P; Ren K; Revelle JK; Kim DC; Scott D; Bjercke RJ; Yeh ET; Beck PJ; Kogan TP
J Immunol; 1997 Feb; 158(4):1710-8. PubMed ID: 9029107
[TBL] [Abstract][Full Text] [Related]
15. The design and synthesis of potent cyclic peptide VCAM-VLA-4 antagonists incorporating an achiral Asp-Pro mimetic.
Fotouhi N; Joshi P; Fry D; Cook C; Tilley JW; Kaplan G; Hanglow A; Rowan K; Schwinge V; Wolitzky B
Bioorg Med Chem Lett; 2000 Jun; 10(11):1171-3. PubMed ID: 10866374
[TBL] [Abstract][Full Text] [Related]
16. Solid state structural analysis of the cyclooctapeptide cyclo- (Pro1-Pro-Phe-Phe-Ac6c-Ile-D-Ala-Val8).
Saviano M; Isernia C; Rossi F; Di Blasio B; Iacovino R; Mazzeo M; Pedone C; Benedetti E
Biopolymers; 2000 Feb; 53(2):189-99. PubMed ID: 10679623
[TBL] [Abstract][Full Text] [Related]
17. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and immunosuppressive activity of glycine containing linear analogs of cyclolinopeptide A.
Siemion IZ; Cebrat M; Pédyczak A; Zimecki M; Wieczorek Z
Arch Immunol Ther Exp (Warsz); 1993; 41(5-6):285-9. PubMed ID: 8010867
[TBL] [Abstract][Full Text] [Related]
19. Design of novel bicyclic analogues derived from a potent oxytocin antagonist.
Flouret G; Chaloin O; Borovickova L; Slaninová J
J Pept Sci; 2006 Jun; 12(6):412-9. PubMed ID: 16432806
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships of novel cyclic alpha-MSH/beta-MSH hybrid analogues that lead to potent and selective ligands for the human MC3R and human MC5R.
Balse-Srinivasan P; Grieco P; Cai M; Trivedi D; Hruby VJ
J Med Chem; 2003 Aug; 46(17):3728-33. PubMed ID: 12904077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
